Spots Global Cancer Trial Database for Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Official Title: A Phase II Evaluation Of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989) In The Treatment Of Persistent Or Recurrent Endometrial Carcinoma

Study ID: NCT00096447

Conditions

Recurrent Endometrial Carcinoma

Interventions

lapatinib ditosylate

Study Description

Brief Summary: This phase II trial is studying how well lapatinib works in treating patients with recurrent or persistent endometrial cancer. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth

Detailed Description: PRIMARY OBJECTIVES: I. Determine the 6-month progression-free survival of patients with recurrent or persistent endometrial carcinoma treated with lapatinib. II. Determine the nature and degree of toxicity of this drug in these patients. SECONDARY OBJECTIVES: I. Determine the objective response rate in patients treated with this drug. II. Determine the duration of progression-free survival and overall survival in patients treated with this drug. III. Determine the effects of prognostic factors, such as initial performance status and tumor grade, in patients treated with this drug. OUTLINE: This is a multicenter study. Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 22-82 patients will be accrued for this study within 30-67 months.